Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of WX390 in Patients With Advanced Solid Tumors
Sponsor: Shanghai Jiatan Pharmatech Co., Ltd
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients with advanced solid tumors. The main questions it aims to answer are: * PFS, OS, DoR at week 48; * antitumor effects at week 24 and week 48. Participants will be treated with WX390 orally, and follow the efficacy and safety evaluation according to the protocol.
Official title: An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of WX390 in Patients With Advanced Solid Tumors
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2021-05-11
Completion Date
2026-06-12
Last Updated
2024-11-19
Healthy Volunteers
No
Conditions
Interventions
WX390
WX390 tablet, 1.1 mg once a day
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China